Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

279
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
279
Development of Immunocompetence01:22

Development of Immunocompetence

1.1K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.1K
Vaccinations01:51

Vaccinations

53.2K
Overview
53.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The optimal procedure of modified Rex shunt for the treatment of extrahepatic portal hypertension in children.

Journal of vascular surgery. Venous and lymphatic disorders·2017
Same author

Dihydromyricetin protects against lipopolysaccharide‑induced cardiomyocyte injury through the toll‑like receptor‑4/nuclear factor‑κB pathway.

Molecular medicine reports·2017
Same author

BIO alleviated compressive mechanical force-mediated mandibular cartilage pathological changes through Wnt/β-catenin signaling activation.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2017
Same author

Structural and mechanistic insights into the biosynthesis of CDP-archaeol in membranes.

Cell research·2017
Same author

Decreased expression of hsa‑miR‑372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1.

Molecular medicine reports·2017
Same author

Autophagy is activated to protect renal tubular epithelial cells against iodinated contrast media‑induced cytotoxicity.

Molecular medicine reports·2017

Related Experiment Video

Updated: Mar 14, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.5K

The Density Code for the Development of a Vaccine?

Wei Cheng1

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109; Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109; Department of Biophysics, University of Michigan, Ann Arbor, Michigan 48109.

Journal of Pharmaceutical Sciences
|September 22, 2016
PubMed
Summary

Vaccine development is often empirical. This review highlights antigen density on vaccine carriers as a key factor for successful viral vaccines and humoral immunity.

Keywords:
B-cell activationB-cell receptorimmune responseimmunologynanoparticlesparticulate antigenprotein densityvaccine deliveryvaccines

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.8K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Related Experiment Videos

Last Updated: Mar 14, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.5K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.8K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Area of Science:

  • * Virology
  • * Immunology
  • * Vaccinology

Background:

  • * Viral vaccine development lacks standardized strategic rules, relying heavily on empirical methods.
  • * Fifteen licensed viral vaccines exist in the U.S. from 12 virus families, with substantial structural and mechanistic data available.
  • * Understanding humoral immunity from viral vaccines requires quantitative analysis of viral surface antigens.

Purpose of the Study:

  • * To review quantitative features of viral surface antigens.
  • * To explore the correlation between immunogenic protein density and vaccine success.
  • * To emphasize the role of antigen density in immune system activation for vaccine formulation.

Main Methods:

  • * Review of existing structural and mechanistic data for licensed viral vaccines.
  • * Analysis of quantitative features of viral surface antigens.
  • * Correlation analysis between antigen density and vaccine efficacy.

Main Results:

  • * A potential correlation exists between the density of immunogenic proteins on vaccine carriers and vaccine success.
  • * Antigen density is crucial for quantitative understanding of humoral immunity induced by viral vaccines.
  • * Both antigen carrier size and immunogenic protein density are important parameters for vaccine formulation.

Conclusions:

  • * Antigen density is a critical factor influencing the success of viral vaccines.
  • * Optimizing antigen carrier size and immunogenic protein density may enhance vaccine efficacy.
  • * Further research is needed to fully elucidate the mechanisms underlying antigen density's impact on immune activation.